Indication
Infantile Fibrosarcoma
3 clinical trials
3 products
Clinical trial
A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System TumorsStatus: Recruiting, Estimated PCD: 2024-12-15
Product
LOXO-292Product
LarotrectinibClinical trial
A Comparison of Clinical Outcomes in Infantile Fibrosarcoma (IFS) Patients Treated With Larotrectinib in the Phase I/II SCOUT Study Versus (an) External Historical Cohort(s)Status: Completed, Estimated PCD: 2022-09-13
Product
Standard of CareClinical trial
Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute LeukemiasStatus: Active (not recruiting), Estimated PCD: 2024-09-30